Preclinical evaluation of the novel 7-substituted camptothecin Namitecan (ST1968) in paediatric tumour models (Q39272645)

10 September 2017

Preclinical evaluation of the novel 7-substituted camptothecin Namitecan (ST1968) in paediatric tumour models (English)

1 reference

10 September 2017

Daniela Meco

1

0 references

Riccardo Riccardi

object named as

Riccardo Riccardi

9

0 references

author name string

Angela Maria Di Francesco

2

1 reference

10 September 2017

Gabriella Cusano

3

1 reference

10 September 2017

Federica Bucci

4

1 reference

10 September 2017

Filomena Pierri

5

1 reference

10 September 2017

Valentina Patriarca

6

1 reference

10 September 2017

Anna Rita Torella

7

1 reference

10 September 2017

Claudio Pisano

8

1 reference

10 September 2017

25 September 2012

1 reference

Cancer Chemotherapy and Pharmacology

10 September 2017

1 reference

10 September 2017

70

1 reference

10 September 2017

6

1 reference

10 September 2017

811-822

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-012-1973-0

10 September 2017

0 references

cites work

Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1973-0

Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1973-0

Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1973-0

Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1973-0

Intracellular accumulation and DNA damage persistence as determinants of human squamous cell carcinoma hypersensitivity to the novel camptothecin ST1968.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1973-0

Preclinical efficacy of ST1976, a novel camptothecin analog of the 7-oxyiminomethyl series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1973-0

The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1973-0

Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1973-0

Induction of DNA single-strand breaks in human lymphocytes by low doses of gamma-rays

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1973-0

The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: a comparative study with SN38 and topotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1973-0

Use of the comet assay for assessment of drug resistance and its modulation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1973-0

Fourth International Workgroup on Genotoxicity testing: results of the in vivo Comet assay workgroup

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1973-0

The development of camptothecin analogs in childhood cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1973-0

Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1973-0

Prolonged low-dose administration of the cyclooxygenase-2 inhibitor celecoxib enhances the antitumor activity of irinotecan against neuroblastoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1973-0

The selective Trk inhibitor AZ623 inhibits brain-derived neurotrophic factor-mediated neuroblastoma cell proliferation and signaling and is synergistic with topotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1973-0

Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1973-0

Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1973-0

Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1973-0

10.1007/S00280-012-1973-0

21 January 2018

Identifiers

DOI

1 reference

10 September 2017

1 reference